Fundraising FoxThird Rock Ventures — 2025 Investments
7 investments dated 2025 · listed companies and verified rows first · show all
Azalea Therapeutics develops precision genome editing therapies that engineer T cells directly inside the patient's body to create cancer immunotherapies, using proprietary delivery vehicles to target and modify specific genetic loci without ex vivo cell manipulation.
AI & Machine LearningBiotechMedical DevicesSan Francisco, US
Jennifer Doudna(Co-founder, Nobel Laureate in Chemistry and Li Ka Shing Chancellor's Chair in Biomedical and Health Sciences, UC Berkeley)Rodolphe Barrangou(Co-founder, Associate Professor of Medicine, UCSF)Krishnendu Roy(Co-founder, Professor of Bioengineering, Stanford University)Connor Tsuchida(Scientific Cofounder)in
Co-investorsRA CapitalSozo VenturesYosemite
Syremis Therapeutics is a clinical-stage biopharmaceutical company developing neuropsychiatric medicines based on mechanisms including muscarinic M1/M4 agonism and NMDA antagonism.
BiotechHealthtechMental Health
Co-investorsGV (Google Ventures)Bain Capital Life Sciences
Developer of a transcatheter InterAtrial Shunt Device to treat congestive heart failure.
BiotechTewksbury, US
George J. Fazio(Executive Officer, Director)inDan B. Curtis(Executive Officer)
BoardPaul LaViolette(Director)inGerald Brunk(Director)inIrit Yaniv(Director)in
Board seatKevin GillisMark Levin· per SEC Form D
Co-investorsAccelmed PartnersLumira VenturesGeneral CatalystSV Health Investors
.png)
Kamal Therapeutics is developing an intravenous recombinant human decorin as a treatment for dystrophic epidermolysis bullosa.
BiotechHealthtechHingham, US
Mark de Souza(Executive Officer, Director)Alexander Silver(Director)Hal Landy(Director)Joff Masukawa(Director)Deborah Ramsdell(Executive Officer, Director)
Board seatPhilip Reilly· per SEC Form D · $17.3M raise · filed Nov 2025
Develops programmable mRNA therapies that last longer and target cells more precisely for cancer and other diseases.
BiotechBoston, US
Tasuku Kitada(Executive Officer, Director, Promoter)inJacob Becraft(Executive Officer, Director, Promoter)inSamta Kundu(Executive Officer)in
BoardAla Alenazi(Director)inPegah Ebrahimi(Director)in
Board seatJeb Keiper· per SEC Form D · $120.1M raise · filed Mar 2026
Co-investorsJIC Venture Growth InvestmentsKinnevikPlayground GlobalAmgen VenturesANRIFPV+3 more
TRIANA Biomedicines is a venture-backed biopharmaceutical company developing small-molecule "molecular glue" therapeutics that induce protein:protein interactions to degrade or alter disease-causing target proteins, with an initial focus on targeted protein degradation for cancer.
BiotechDeep TechHealthtechLexington, US
Patrick Trojer(President & Chief Executive Officer)in
Board seatJigar Raythatha· per SEC Form D · $120.1M raise · filed Dec 2025
Co-investorsAscenta CapitalAtlas VentureLightspeed Venture PartnersRA CapitalBessemer Venture PartnersPfizer Ventures+3 more
ARTBIO develops alpha radioligand therapies (ARTs) for cancer treatment, designing target-and-molecule combinations intended to kill tumors while sparing healthy tissue.
BiotechHealthtechMedical DevicesOslo, NO
Roy Larsen(Scientific Co-Founder)Øyvind Bruland(Scientific Co-Founder; SAB Chairman)Margaret Yu(Chief Medical Officer)inPhilippe Dasse(Chief Technical Officer)inAmra Demirovic(Chief Human Resources Officer)inNicole Hadas(Chief Legal Officer)
Co-investorsB Capital GroupB4 CapitalF-Prime CapitalSofinnova VenturesAlexandriaB Capital+2 more
.jpeg){kind=logo}
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.